BTK
BTK (Bruton's tyrosine kinase) inhibitors are compounds that specifically target and inhibit BTK, a crucial enzyme involved in B-cell receptor signaling and the regulation of angiogenesis. BTK plays a significant role in the proliferation and survival of cancer cells, particularly in hematological malignancies. By inhibiting BTK, these compounds can disrupt angiogenesis and tumor growth, making them valuable in cancer therapy. At CymitQuimica, we offer a range of high-quality BTK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 165 products for "BTK".
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Formula:C25H23ClN6O3Purity:99.27% - 99.95%Color and Shape:SolidMolecular weight:490.94MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Formula:C41H41N9O8Purity:95.93% - 97.60%Color and Shape:SolidMolecular weight:787.82Ref: TM-T16157
1mg92.00€5mg177.00€1mL*10mM (DMSO)231.00€10mg269.00€25mg510.00€50mg692.00€100mg888.00€200mg1,251.00€IBT6A
CAS:IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Formula:C22H22N6OPurity:99.88% - 99.88%Color and Shape:SolidMolecular weight:386.45AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Formula:C33H31FN6O3Purity:≥95%Color and Shape:SolidMolecular weight:578.64Rilzabrutinib
CAS:Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Formula:C36H40FN9O3Purity:98.28% - 99.76%Color and Shape:SolidMolecular weight:665.76Ref: TM-T12542
1mg94.00€5mg222.00€1mL*10mM (DMSO)325.00€10mg356.00€25mg620.00€50mg893.00€100mg1,251.00€500mg2,502.00€ARQ 531
CAS:ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Formula:C25H23ClN4O4Purity:98.68% - 99.63%Color and Shape:SolidMolecular weight:478.93Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Formula:C24H25N5O3Purity:99.94%Color and Shape:SolidMolecular weight:431.49Ref: TM-T10629
1mg34.00€2mg49.00€5mg74.00€1mL*10mM (DMSO)82.00€10mg98.00€25mg215.00€50mg356.00€100mg434.00€Acalabrutinib enantiomer
CAS:R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.Formula:C26H23N7O2Purity:99.20%Color and Shape:SolidMolecular weight:465.51Ref: TM-T67881
200mgTo inquire1mg80.00€5mg168.00€1mL*10mM (DMSO)178.00€10mg238.00€25mg379.00€50mg513.00€100mg707.00€Orelabrutinib
CAS:Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Formula:C26H25N3O3Purity:97.77% - 99.54%Color and Shape:SolidMolecular weight:427.49Ref: TM-T12317
1mg86.00€5mg177.00€1mL*10mM (DMSO)205.00€10mg299.00€25mg492.00€50mg682.00€100mg897.00€500mg1,791.00€NRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Formula:C43H51N11O6Color and Shape:SolidMolecular weight:817.94BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Color and Shape:Odour SolidBTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Formula:C25H24F3N7O3Color and Shape:SolidMolecular weight:527.508DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formula:C55H62N10O8Color and Shape:SolidMolecular weight:991.163FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Color and Shape:LiquidRef: TM-L1610
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireSJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Formula:C41H45ClN8O7Purity:98%Color and Shape:SolidMolecular weight:797.3PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Formula:C47H54F2N8O13Color and Shape:SolidMolecular weight:976.97Ibrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Formula:C56H80N12O9SPurity:98%Color and Shape:SolidMolecular weight:1097.39CNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Formula:C48H68N10O9SPurity:98%Color and Shape:SolidMolecular weight:961.18TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Color and Shape:Odour SolidFDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Color and Shape:Odour Solid
